Announcements Trials

Browse Landscape

Phase

Phase 2 1 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Pancreatic Neoplasms 3 Neoplasms 1 Melanoma 1 Lung Neoplasms 1 Liver Neoplasms 1 Liver Metastasis Colon Cancer 1 Kidney Neoplasms 1 Colorectal Neoplasms 1 Carcinoma, Renal Cell 1 Carcinoma, Hepatocellular 1

Interventions

pembrolizumab 6 aldesleukin 6 Cyclophosphamide 6 fludarabine phosphate 5 fludarabine 5 Nivolumab 4 durvalumab 3 Sorafenib 3 Radiotherapy 3 Filgrastim 3 Everolimus 3 Axitinib 3 Temozolomide 2 Peripheral Blood Stem Cell Transplantation 2 Isotretinoin 2 Ipilimumab 2 Interleukin-2 2 Interferon-alpha 2 Fluorouracil 2 Dexamethasone 2 Cyclosporine 2 Bevacizumab 2 vorolanib 1 tremelimumab 1 tocilizumab 1 talazoparib 1 spartalizumab 1 sargramostim 1 poly ICLC 1 palbociclib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Kidney Neoplasms × Electroporation × Clear all

NCT02298608 2014-11-24

Efficacy and Safety of IRE for RMs

Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

Phase 1/2 Unknown

Kidney Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡